The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
NCT07346053
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
224
Enrollment
OTHER
Sponsor class
Conditions
Advanced Bladder Cancer
Interventions
DRUG:
enfortumab vedotin and pembrolizumab (EV/P)
Sponsor
Guliz Ozgun
Collaborators
[object Object]